ArticleFrontiers in oncology2022
Metastasis patterns and prognosis in young breast cancer patients: A SEER database analysis.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Breast Cancer Liver Metastasis: Primary tumor predictors and histopathologic characteristics of metastatic lesions.Research square · 2026Article
- Patient-Reported Quality of Life Predicts First-Cycle Pharmacotherapy Survival in Breast Cancer: A Prospective Cohort Study.Medical sciences (Basel, Switzerland) · 2026Article
- Unmet support and information needs of relatives of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Influencing factors of axillary lymph node metastasis and prognosis in patients with T2 breast cancer.Gland surgery · 2025Article
- Survival Analysis of Metastatic Young-Onset vs. Average-Onset Cholangiocarcinoma: A Population-Based Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study.BMC cancer · 2025Article
- Clinical profile and outcomes of young women with denovo-metastatic breast cancer: real-world data from a tertiary care centre in India.Ecancermedicalscience · 2025Article
- Risk factors for secondary thyroid cancer in patients with breast cancer: a propensity‑matched SEER analysis.Scientific reports · 2024Article
- Assessing Trends in Hospitalizations for Breast Cancer among Women in Korea: A Utilization of the Korea National Hospital Discharge In-depth Injury Survey (2006-2020).Journal of epidemiology and global health · 2024Article
- Metastasis patterns and prognosis in young gastric cancer patients: A propensity score‑matched SEER database analysis.PloS one · 2024Article
- Cancer Stem Cells are Actually Stem Cells with Disordered Differentiation: the Monophyletic Origin of Cancer.Stem cell reviews and reports · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are few studies on young patients with metastatic breast cancer (MBC). This study aims to explore the metastasis pattern and prognosis of young patients with MBC. Methods: A total of 6,336 MBC patients diagnosed in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were selected. They were divided into two age groups: the younger group (≤40 years old) and the older group (>40 years old). χ Results: Finally, 494 patients (7.8%) who are ≤40 years old and 5,842 patients (92.2%) who are >40 years old were included. In the younger group, the proportion of liver metastasis was significantly higher than that in the older group; the proportion of lung metastasis was significantly lower than that of the older group. Kaplan-Meier analysis showed that the younger group had the best prognosis and the older group had the worst. Youth is an independent protective factor for overall survival (OS). In the younger group, liver metastasis had the best prognosis among all metastatic sites, and the HER2-enriched subtype had the best prognosis among all subtypes. Conclusions: The disease in young MBC patients is more aggressive but has a better prognosis, especially in liver metastases and the HER2-enriched subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.